Stock Price Effects of FDA Announcements on Prescription Drugs
Date
2014-09-26
Authors
Contributor
Advisor
Department
Instructor
Depositor
Speaker
Researcher
Consultant
Interviewer
Narrator
Transcriber
Annotator
Journal Title
Journal ISSN
Volume Title
Publisher
University of Hawaii at Manoa
Volume
Number/Issue
Starting Page
Ending Page
Alternative Title
Abstract
The pharmaceutical industry has continually been one of the highest performing areas in the equity market for many decades. Though the returns on investment are very high, so is the volatility of individual stocks. The purpose of this paper is to analyze the volatility that specific stocks experience when the company's individual drug is approved or disapproved by the Federal Drug Administration (FDA). The development of a new drug usually runs in the high millions of dollars (Over $150 million after taxes); if accepted, it can translate to billions in revenue for the company over the drug's marketable life. Through analyzing the data of stocks' performance during a time window of approval and disapproval announcement dates, this paper will try to gauge the positive aspects of approval, the negative aspects of disapproval, and the levels of variation in both instances. This paper focuses on the notion that FDA disapproval of a drug will cause a high percentage drop in the stock price, more so than for the percentage gain a stock's price will experience from approval.
Description
Keywords
Citation
Extent
24 pages
Format
Geographic Location
Time Period
Related To
Related To (URI)
Table of Contents
Rights
All UHM Honors Projects are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission from the copyright owner.
Rights Holder
Local Contexts
Collections
Email libraryada-l@lists.hawaii.edu if you need this content in ADA-compliant format.